# Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease

> **NCT02458014** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 36 (actual)

## Conditions studied

- Adult Acute Lymphoblastic Leukemia in Complete Remission
- B Acute Lymphoblastic Leukemia
- Minimal Residual Disease
- Philadelphia Chromosome Positive

## Interventions

- **BIOLOGICAL:** Blinatumomab
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02458014
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-14
- **Primary completion:** 2025-09-16
- **Final completion:** 2025-09-16
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02458014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02458014, "Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02458014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*